Neoadjuvant Immunotherapy for T4 dMMR Colon Cancer

Sponsor
Peking Union Medical College Hospital
Study ID
NCT06215677
Phase
PHASE2
Status
Active Not Recruiting

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Camrelizumab — DRUG
    Camrelizumab 200mg for 3 cycles. Patients will undergo surgery 2-3 weeks after the last cycle of immunotherapy, type and extent of the surgery will be selected by the surgeon.

Study Details

Due to dMMR colon cancer patients respond poorly to conventional chemotherapy, but immunotherapy can significantly improve the pCR in this group of patients, this study intends to explore whether neoadjuvant immunotherapy can improve the R0 resection rate with preservation of adjacent organs in T4 colon cancer patients with dMMR.

Key Dates

First listed
Jan 22, 2024
Start date
Jan 1, 2024
Status verified
Jun 2026
Primary completion
May 10, 2025
Completion
Feb 10, 2028

Study Design

Enrollment
18 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Neoadjuvant immunotherapy

Primary Outcome Measure

the rate of R0 resection [ Time Frame: Tumour specimen evaluated within 2 weeks after surgery ]

Find similar trials

Nationwide
Colorectal cancer trialsOncology trialsGI oncology trials

Related Studies